AbbVie(ABBV)

NORTH CHICAGO, ILPharmaceutical2 H-1B visas (FY2023)

Focus: AbbVie is a $54B revenue Big Pharma company with a diversified portfolio spanning immunology, oncology, neuroscience, aesthetics, and eye care across small molecules and biologics. With 50,000 employees, it ranks among the top 10 global pharmaceutical companies by revenue.

Immunology Oncology Neuroscience Aesthetics

Profile data last refreshed 18h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

50,000

Open Jobs

Recent layoff filing — 2 affected

11/10/2025 — 4410 Rosewood Drive Pleasonton CA 94588, CA · 2 affected · Closure

Source: state DOL filings via Big Local News

About AbbVie

AI assessmentNot Hiring

No open roles listed right now. Follow AbbVie to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

6/9 — Partial

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

7 imminent

ACULAR LS

Hiring

Stable

Revenue

$54.3B

FY2025

Key Products

IMBRUVICA

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma

$2.4B Part D

Peak

Help build intelligence for AbbVie

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established Big Pharma scale with $54.3B FY2025 revenue and $7.7B R&D spend provides career stability, extensive training, and exposure to global operations
Diversified therapeutic portfolio across 5 major areas (immunology, oncology, neuroscience, aesthetics, eye care) with both blockbuster products and emerging pipeline programs enables cross-functional growth
Active hiring of 816 open roles with strong commercial (156) and medical affairs (142) expansion signals growth trajectory and promotion opportunities

Watch Out For

19% revenue concentration in IMBRUVICA with LOE in 2035 creates medium-term patent cliff risk; VRAYLAR patent expiry in 2030 ($936M at risk) may trigger restructuring within 5 years
Pipeline is early-stage heavy (mostly Phase 1-2) with only 3 Phase 3 programs, indicating limited near-term catalysts and potential for delayed revenue growth post-2030

Generated by Claude from AbbVie's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Core revenue driver (19% of company) with 10-year patent protection; sustained by diverse hematologic indications and Bcell inhibitor market leadership.

LINZESS

Irritable Bowel Syndrome with Constipation, Chronic Idiopathic Constipation

$1.8B Part D

Peak7.7yr

Second-largest revenue contributor in GI; faces generic pressure in 2034 but maintains market share in niche bowel disorder segment.

RESTASIS

Dry Eye Disease, Keratoconjunctivitis Sicca

$1.5B Part D

Peak8.0yr

Monopoly in immunomodulatory dry eye; approaching LOE but sustained by label expansion potential and Phase 3 ABBV-444 successor in development.

CREON

Exocrine Pancreatic Insufficiency, Cystic Fibrosis, Chronic Pancreatitis

$1.5B Part D

LOE Approaching

Enzyme replacement therapy facing generic erosion; narrow indication base limits growth despite chronic disease patient population.

RINVOQ

Rheumatoid Arthritis, Atopic Dermatitis, Ulcerative Colitis

$976M Part D

Peak11.8yr

JAK inhibitor with longest patent protection (2038) and expanding label footprint across immunology; key growth driver for next 10 years.

VRAYLAR

Schizophrenia, Bipolar I Disorder

$936M Part D

Peak3.8yr

Atypical antipsychotic with upcoming 2030 patent cliff; faces competitive CNS market pressure from other atypicals and mechanism-novel agents.

VENCLEXTA

Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia

$815M Part D

Peak7.3yr

BCL-2 inhibitor with broad hematologic label and strong clinical data; faces LOE in 2033 but maintains strong oncology franchise positioning.

Pipeline & Clinical Trials

veliparib

Triple Negative Breast Cancer

N/A

Clinical Trials (5)

NCT02470585Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3

NCT02106546Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Phase 3

NCT02163694A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Phase 3

+2 more

Pembrolizumab

Metastatic Non Small Cell Lung Cancer

N/A

Clinical Trials (2)

NCT06772623Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Phase 1/2

NCT04274907

A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Me

Uterine Fibroids (UF)

N/A

Clinical Trials (1)

NCT06058728A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

N/A

A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Sma

Non Small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT06068842A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer

N/A

rovalpituzumab tesirine

Small Cell Lung Cancer

N/A

Clinical Trials (5)

NCT03061812Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

Phase 3

NCT03334487

navitoclax

Myelofibrosis

N/A

Clinical Trials (5)

NCT04468984Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Phase 3

NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

ABBV-787

Acute Myeloid Leukemia

N/A

Clinical Trials (2)

NCT06068868Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Phase 1

NCT06439966Expanded Access to ABBV-787

tavapadon

Parkinson Disease

N/A

Clinical Trials (5)

NCT04201093Fixed-Dose Trial in Early Parkinson's Disease (PD)

Phase 3

NCT04542499Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)

Phase 3

glecaprevir/pibrentasvir

Hepatitis C Virus Infection

N/A

Clinical Trials (5)

NCT03781726Multi-center Study to Transplant Hepatitis-C Infected Kidneys

Phase 4

NCT03219216A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

ubrogepant

Migraine

N/A

Clinical Trials (5)

NCT05503082Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies

Phase 4

NCT05264129Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine

foslevodopa/foscarbidopa

Parkinson's Disease

N/A

Clinical Trials (5)

NCT07227896Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

N/A

NCT07284342A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa

Technetium labelled glucosamine

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT0178915199m-Technetium- Glucosamine in Arthritis

N/A

A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants Wit

Chronic Lymphocytic Leukemia

N/A

Clinical Trials (1)

NCT06125795A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain

N/A

Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Obse

Chronic Hepatitis C

N/A

Clinical Trials (1)

NCT02582658Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)

N/A

Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa

Parkinson's Disease

N/A

Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoria

Psoriatic Arthritis

N/A

No Intervention

Diabetic Retinopathy, DR

N/A

Clinical Trials (1)

NCT05296447Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy

N/A

A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Mo

Arthritis

N/A

A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection i

Respiratory Syncytial Virus Infection

N/A

Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Art

Rheumatoid Arthritis

N/A

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Moderate-to-severe Rheumatoid Arthritis

N/A

Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT02627924Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab

N/A

Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Ru

Genital Endometriosis

N/A

A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Select

Secondary Hyperparathyroidism

N/A

Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol

Kidney Failure, Chronic

N/A

Surveillance of Humira in Korean JIA Patients

Polyarticular Juvenile Idiopathic Arthritis

N/A

Clinical Trials (1)

NCT02141984Surveillance of Humira in Korean JIA Patients

N/A

Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidi

Moderate to Severe Plaque Psoriasis

N/A

TNF-α antagonists, non-TNFs, DMARD non-biologics

Rheumatoid Arthritis

N/A

An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chin

Polyarticular Juvenile Idiopathic Arthritis

N/A

Clinical Trials (1)

NCT05411211An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)

N/A

Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir

Chronic Hepatitis C (CHC)

N/A

Clinical Trials (1)

NCT03868163Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation

N/A

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerati

Ulcerative Colitis (UC)

N/A

Clinical Trials (1)

NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

N/A

A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult

Myelofibrosis

N/A

Clinical Trials (1)

NCT05444972A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

N/A

Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT01783730Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents

N/A

A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic

Hepatitis C Virus (HCV)

N/A

Clinical Trials (1)

NCT04214028A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus

N/A

Observational Study to Explore the Effectiveness of Adalimumab Treatment in Conjunction With Utiliza

Rheumatoid Arthritis

N/A

A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Ko

Ulcerative Colitis

N/A

Clinical Trials (1)

NCT02499263A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice

N/A

The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France

Chronic Hepatitis C

N/A

Clinical Trials (1)

NCT02618928The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France

N/A

Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical

Rheumatoid Arthritis

N/A

ULTRESA

Fibrosing Colonopathy

N/A

Clinical Trials (1)

NCT01652157Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

N/A

Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Co

Moderate to Severe Ulcerative Colitis

N/A

Clinical Trials (1)

NCT02092389Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo

N/A

Ombitasvir/paritaprevir/ritonavir

Chronic Hepatitis C

N/A

Clinical Trials (1)

NCT02582671The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland

N/A

Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (M

Multiple Myeloma (MM)

N/A

Clinical Trials (1)

NCT04721002Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)

N/A

Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1

Chronic Hepatitis C Virus

N/A

Clinical Trials (1)

NCT02629172Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1

N/A

Clinical Practice of Inhalation Anesthesia With Sevoflurane in China

Anesthesia, General

N/A

EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosi

Ankylosing Spondylitis (AS)

N/A

Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoria

Moderate to Severe Psoriasis

N/A

Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankyl

Ankylosing Spondylitis

N/A

A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and

HIV Infection

N/A

Long- and intermediate- acting insulins

Diabetes

N/A

Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)

Ankylosing Spondylitis

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 427 approved products, 160 clinical trials

Top TAs: Oncology, Ophthalmology, Immunology

H-1B (2023): 2 approvals

Publications: 50 in PubMed

SEC Filings: 2 available

Portfolio Health

Pre-Launch95 (22%)

Launch1 (0%)

Growth4 (1%)

Peak45 (11%)

LOE Approaching175 (41%)

Post-LOE107

Therapeutic Area Focus

Oncology

67 marketed374 pipeline

Ophthalmology

34 marketed255 pipeline

Immunology

33 marketed222 pipeline

Neurology

63 marketed182 pipeline

Financials (FY2025)

Revenue

$54.3B6%

R&D Spend

$7.7B(14%)18%

Net Income

$4.9B

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (1)

2025-11-10

2 employees affected— 4410 Rosewood Drive Pleasonton CA 94588, CA

source

Source: state DOL filings, aggregated via Big Local News

No disclosed regulatory warnings, FDA actions, or workforce reductions in available data; however, declining profitability (2024-2025) and cash compression warrant monitoring for potential restructuring announcements in H2 2025.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Circulating Exosomal MicroRNAs as Potential Biomarkers for Pulmonary Embolism.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

2026

PMID:41773945

Visual Outcomes Following Infectious Endophthalmitis from Intravitreal Injections of Biologic Drugs: An Intelligent Research in Sight Registry Retrospective Analysis.

SUBLINGUAL · TABLET

disorder, is unknown. It has been suggested that the efficacy of asenapine in schizophrenia could be mediated through a combination of antagonist activity at D 2 and 5-HT 2A receptors.

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT03033511A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

Phase 3

NCT01828476Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

Phase 2

NCT04223193Flexible-Dose Trial in Early Parkinson's Disease (PD)

Phase 3

NCT03212521Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Phase 3

NCT05125302Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Phase 3

NCT06916507Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)

N/A

64 marketed137 pipeline

Cardiovascular

58 marketed91 pipeline

Gastroenterology

33 marketed36 pipeline

Metabolic Diseases

24 marketed21 pipeline

Ophthalmology and therapy

2026

PMID:42033607

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

AbbVie(ABBV)

About AbbVie

Why Work Here

Key Products

Watch Out For

Products & Portfolio (72)

Key Products by Revenue

Other Products (33)

Pipeline & Clinical Trials

Recent News · AbbVie(10)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (1)

Research Publications(10)